Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome

被引：0
|
作者：
Kibum Kim
Daniel R. Touchette
Larisa H. Cavallari
Amer K. Ardati
Robert J. DiDomenico
机构：
[1] University of Utah,Department of Pharmacotherapy and Pharmacotherapy Outcomes Research Center
[2] University of Illinois at Chicago,Center for Pharmacoepidemiology and Pharmacoeconomic Research
[3] University of Illinois at Chicago,Department of Pharmacy Systems, Outcomes and Policy
[4] University of Florida,Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics
[5] University of Illinois at Chicago,Division of Cardiology
[6] University of Illinois at Chicago,Department of Pharmacy Practice
来源：
Cardiovascular Drugs and Therapy | 2019年 / 33卷
关键词：
Acute coronary syndrome; Personalized medicine; Ticagrelor; Clopidogrel; P2Y; inhibitors; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：533 / 546
页数：13
相关论文
共 50 条
  • [21] Comparative Effectiveness of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome and Co-Morbid Diabetes Mellitus: A Cohort Study
    Spoendlin, Julia
    Gagne, Joshua J.
    Lewey, Jennifer
    Desai, Rishi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 439 - 440
  • [22] Combined Use of Warfarin and Oral P2Y12 Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome
    Jones, William S.
    Mi, Xiaojuan
    Patel, Manesh R.
    Mills, Rogers
    Hernandez, Adrian F.
    Curtis, Lesley H.
    CIRCULATION, 2013, 128 (22)
  • [23] Effect of new p2y12 inhibitors in patients with chronic kidney disease after an acute coronary syndrome
    Deharo, P.
    Pankert, M.
    Bonnet, G.
    Quilici, J.
    Bonnet, J. L.
    Cuisset, T.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1163 - 1163
  • [24] DURATION AND TIMING OF INITIATION OF THERAPY WITH PLATELET P2Y12 INHIBITORS IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
    Shalaev, S., V
    Safiullina, Z. M.
    KARDIOLOGIYA, 2018, 58 (03) : 54 - 62
  • [25] Combined Use of Warfarin and Oral P2Y12 Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome
    Jones, W. Schuyler
    Mi, Xiaojuan
    Patel, Manesh R.
    Mills, Roger
    Hernandez, Adrian F.
    Curtis, Lesley H.
    CLINICAL CARDIOLOGY, 2014, 37 (03) : 152 - 159
  • [26] Predictors of newer P2Y12 inhibitors prescription at discharge in a contemporary cohort of patients with acute coronary syndrome
    Gomez-Molina, M.
    Flores-Blanco, P. J.
    Rapodeiras-Rubin, S.
    Abu-Assi, E.
    Cambronero-Sanchez, F.
    Cobas-Paz, R.
    Lopez-Cuenca, A.
    Caneiro-Queija, B.
    Guerrero-Perez, E.
    Valdes, M.
    Iniguez-Romo, A.
    Manzano Fernandez, S.
    EUROPEAN HEART JOURNAL, 2017, 38 : 801 - 801
  • [27] P2Y12 inhibitors in acute coronary syndromes: Which and when?
    Pais, Prem
    NATIONAL MEDICAL JOURNAL OF INDIA, 2013, 26 (02): : 84 - 90
  • [28] Efficacy of genotype guided selection of P2Y12 antagonist for treatment of acute coronary syndrome in Chinese patients
    Kong, S. L.
    Tam, F. C. C.
    Wong, A. Y. T.
    Yung, A. S. Y.
    Shea, P. C.
    Chan, E. K. Y.
    Lam, S. C. C.
    Chan, K. K. W.
    Chan, R. H. W.
    Lee, S. W. L.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1162 - 1162
  • [29] APPROACH OF WITHHOLDING P2Y12 INHIBITORS FOR URGENT CORONARY ARTERY BYPASS GRAFTING IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME
    Seikh, Ghulam Abbas
    Ahmed, Faisal
    Shah, Arshad Ali
    Asad, Syed Dilbahar Ali Shah
    Ashfaq, Fareheen
    Lashari, Muhammad Nawaz
    Lashari, Muhammad Nawaz
    PAKISTAN HEART JOURNAL, 2022, 55 (04): : 346 - 350
  • [30] P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes
    Alexopoulos, Dimitrios
    Varlamos, Charalampos
    Mpahara, Aikaterini
    Lianos, Ioannis
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (10) : 717 - 727
12345